<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902666</url>
  </required_header>
  <id_info>
    <org_study_id>044(1F)PO15313</org_study_id>
    <secondary_id>CRO-PK-15-304</secondary_id>
    <nct_id>NCT02902666</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of One Tablet of Paracetamol 1000 mg + Codeine 30 mg vs. Two Tablets of Paracetamol 500 mg + Codeine 30 mg</brief_title>
  <official_title>A Single Dose Bioequivalence Study of Test Product (One Tablet of Paracetamol 1000 mg + Codeine 30 mg, Manufactured by A.C.R.A.F. S.p.A.) vs. Two Tablets of the Reference Product (Paracetamol 500 mg + Codeine 30 mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of a new paracetamol 1000&#xD;
      mg/codeine 30 mg formulation vs. the marketed reference Co-efferalgan® 500 mg/30 mg in terms&#xD;
      of rate and extent of absorption, when administered as single oral dose (one tablet of the&#xD;
      new A.C.R.A.F. formulation vs. two tablets of the reference formulation Co-efferalgan®) to&#xD;
      healthy male and female volunteers, under fasting conditions, in two consecutive study&#xD;
      periods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of both paracetamol and codeine after administration of one tablet of a new paracetamol 1000 mg/codeine 30 mg formulation vs. two tablets of the marketed reference Co-efferalgan® 500 mg/30 mg (dose normalisation will be applied for codeine).</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
    <description>Maximum plasma concentration (μg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of both paracetamol and codeine after administration of one tablet of a new paracetamol 1000 mg/codeine 30 mg formulation vs. two tablets of the marketed reference Co-efferalgan® 500 mg/30 mg (dose normalisation will be applied for codeine).</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from administration time to the time (t) of the last measurable concentration (Ct), calculated with the linear trapezoidal method (μg*h/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration vs. time curve up to infinity (AUC(0-∞)) of paracetamol and of codeine (free base) after single dose administration of T and R (dose normalisation will be applied to AUC(0-∞), for codeine)</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (h) (Tmax) of paracetamol and of codeine (free base) after single dose administration of T and R (dose normalisation will be applied to AUC(0-∞), for codeine)</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life, calculated, if feasible, as ln2/λz [h] (t1/2,z) of paracetamol and of codeine (free base) after single dose administration of T and R (dose normalisation will be applied to AUC(0-∞), for codeine)</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent First Order Terminal Rate Constant (λz) of paracetamol and of codeine (free base) after single dose administration of T and R (dose normalisation w</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until First Nonzero Concentration (tlag) of paracetamol and of codeine (free base) after single dose administration of T and R (dose normalisation will be applied to AUC(0-∞), for codeine)</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Event (TEAEs), vital signs (BP, HR), physical examinations, laboratory parameters, body weight, ECG</measure>
    <time_frame>0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.&#xD;
Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet</intervention_name>
    <arm_group_label>Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet</intervention_name>
    <arm_group_label>paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent: signed written informed consent before inclusion in the study&#xD;
&#xD;
          2. Sex and Age: males/females, 18-55 years old inclusive&#xD;
&#xD;
          3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive&#xD;
&#xD;
          4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure&#xD;
             (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the&#xD;
             sitting position&#xD;
&#xD;
          5. Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study&#xD;
&#xD;
          6. Tobacco: non-smokers or ex-smokers for at least 6 months&#xD;
&#xD;
          7. Contraception and fertility (females only): females of child-bearing potential must be&#xD;
             using at least one of the following reliable methods of contraception:&#xD;
&#xD;
               1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at&#xD;
                  least 2 months before the screening visit&#xD;
&#xD;
               2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or&#xD;
                  contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap&#xD;
                  with spermicide for at least 2 months before the screening visit&#xD;
&#xD;
               3. A male sexual partner who agrees to use a male condom with spermicide&#xD;
&#xD;
               4. A sterile sexual partner. Female participants of non-child-bearing potential or&#xD;
                  in post-menopausal status for at least 1 year will be admitted. For all female&#xD;
                  subjects, pregnancy test result must be negative at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Electrocardiogram (12-leads, supine position): clinically significant abnormalities&#xD;
&#xD;
          2. Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study&#xD;
&#xD;
          3. Laboratory analyses: clinically significant abnormal laboratory values indicative of&#xD;
             physical illness&#xD;
&#xD;
          4. Allergy: ascertained or presumptive hypersensitivity to the active principle&#xD;
             (paracetamol and/or codeine) and/or formulations' ingredients or related drugs, namely&#xD;
             non-steroidal anti-inflammatory agents and/or opioid derivatives; history of&#xD;
             anaphylaxis to drugs or allergic reactions in general, which the investigator&#xD;
             considers may affect the outcome of the study&#xD;
&#xD;
          5. Diseases: significant history of renal, hepatic, gastrointestinal, genitourinary,&#xD;
             cardiovascular, respiratory (including allergic asthma, allergic or chronic bronchitis&#xD;
             and other pulmonary diseases), skin, haematological, endocrine or neurological&#xD;
             diseases that may interfere with the aim of the study&#xD;
&#xD;
          6. Medications: medications, including over the counter (OTC) medications and herbal&#xD;
             remedies for 2 weeks before the start of the study. Hormonal contraceptives for&#xD;
             females will be allowed&#xD;
&#xD;
          7. Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product for 3 months before this study. The 3-month interval is calculated as the time&#xD;
             between the first calendar day of the month that follows the last visit of the&#xD;
             previous study and the first day of the present study&#xD;
&#xD;
          8. Blood donation: blood donations for 3 months before this study&#xD;
&#xD;
          9. Drug, alcohol, caffeine: history of drug, alcohol [&gt;1 drink/day for females and &gt;2&#xD;
             drinks/day for males, defined according to the USDA Dietary Guidelines 2010], caffeine&#xD;
             (&gt;5 cups coffee/tea/day) abuse&#xD;
&#xD;
         10. Drug test: positive result at the drug test at screening or day-1&#xD;
&#xD;
         11. Alcohol test: positive alcohol breath test at day -1&#xD;
&#xD;
         12. Diet: abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits&#xD;
             in the 4 weeks before this study; vegetarians&#xD;
&#xD;
         13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1,&#xD;
             pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research S.A.</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Paracetamol 1000 mg/codeine 30 mg</keyword>
  <keyword>Co-efferalgan 500 mg/30 mg</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Codeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

